Trial · NCT06650540
Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis
NCT06650540, Not applicable, Not yet recruiting, Peking University Third Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis. Trials, record NCT06650540. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06650540
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis
- NCT number
- NCT06650540
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 800 participants, estimated
- Lead sponsor
- Peking University Third Hospital
- Conditions
- IVF
- Interventions
- Levofloxacin Plus Metronidazole Suppositories, Levofloxacin co-administered with Metronidazole tablets
- First posted
- 2024-10-21
- Last updated
- 2024-10-21
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | live birth rate after the first embryo transfer | 22 weeks to 43 weeks gestation after the first embryo transfer cycle | Live birth is defined as the delivery of at least one baby after 22 weeks of gestation Oversight that exhibits any sign of life. |
| Secondary | Clinical pregnancy | around 7 weeks' gestation after the first embryo transfer cycle | It is defined as at least one gestational sac on ultrasound at around 7 weeks'gestation with the detection of heart-beat activity, |
| Secondary | Ongoing pregnancy | 12 weeks to 43weeks gestation after the first embryo transfer cycle | definedIs pregnancy with detectable heart rate at 12 weeks' gestation or beyond |
| Secondary | Biochemical pregnancy | about 14 days after embryo transfer | defined as a positive pregnancy test |
| Secondary | Miscarriage | 6-22 weeks of gestation | defined as spontaneous loss of a clinical pregnancy before 22 completed weeks of gestational age, in which the embryo(s) or fetus(es) is/are nonviable or is/are absorbed or expelled from the uterus. |
| Secondary | Cumulative live birth | 6 monti after the first embryo transfer | the cumulative rate of live bor children conceived within six months of the first FET cycle. |
| Secondary | Pre-eclampsia | after 20 weeks of gestation | defined as the development of gestational hypertension with proteinuria (≥300 mg/24-hour urine collection or 30 mg/dL. in single urine sample) of new onset after 20 weeks of gestation |
| Secondary | Gestational hypertension | after 20 weeks of gestation | defined as the development of blood pressure greater than 140/90 mmHg after pregnancy without proteinuria or other signs of preeclampsia Time Frame: after 20 weeks of gestation |
| Secondary | Gestational diabetes mellitus | between 24 -28 weeks of gestation | defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy as determined from the diagnosis in the obstetrical medical record |
| Secondary | Premature rupture of membrane(PROM)rate | Time Frame: the day of delivery | defined as rupture of the amniotic membranes before the onset of labor including Measures PROM at term and preterm PROM |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40954081 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06650540
GET https://conductscience.org/api/trials/v1/NCT06650540/registered